AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2024
Dec 14, 2024
32159_dirs_2024-12-13_31f12047-1e18-44f9-9c26-b7bcc0e4ad19.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-12-12
Reporting Person: Chakma Justin (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-12 | Common Stock | M | 117333 | $0.84 | Acquired | 253713 | Direct |
| 2024-12-12 | Common Stock | S | 117333 | $12.2653 | Disposed | 136380 | Direct |
| 2024-12-13 | Common Stock | M | 27272 | $1.44 | Acquired | 163652 | Direct |
| 2024-12-13 | Common Stock | S | 27272 | $12.0625 | Disposed | 136380 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-12 | Stock Option (Right to Buy) | $0.84 | M | 117333 | Disposed | 2029-07-04 | Common Stock (117333) | Direct |
| 2024-12-13 | Stock Option (Right to Buy) | $1.44 | M | 27272 | Disposed | 2031-12-13 | Common Stock (27272) | Direct |
Footnotes
F1: The weighted average sale price for the transaction reported was $12.2653, and the range of prices were between $11.83 and $12.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2: The weighted average sale price for the transaction reported was $12.0625, and the range of prices were between $11.83 and $12.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: Immediately exercisable.